Literature DB >> 14750569

Prophylaxis of acute posttraumatic bacterial endophthalmitis with or without combined intraocular antibiotics: a prospective, double-masked randomized pilot study.

M Soheilian1, N Rafati, G A Peyman.   

Abstract

PURPOSE: The effectiveness of an intraocular injection of combined gentamicin and clindamycin in the prevention of acute posttraumatic bacterial endophthalmitis following penetrating ocular injuries was evaluated in a prospective, double-masked, randomized pilot study.
METHODS: Sixty eyes of 60 patients with penetrating ocular injuries were treated at a tertiary care hospital. Following primary repair, the eyes were randomized in two groups. Group 1, the antibiotic injection group (cases), was given an intracameral or intravitreal injection of 0.1 mL antibiotic (40 microg gentamicin and 45 microg clindamycin). Group 2 (balanced saline solution [BSS] injection group [controls]) received intracameral or intravitreal injection of 0.1 mL BSS. All patients received standard prophylactic antibiotic therapy (systemic, subconjunctival, and topical). RESULT: Although the overall incidence of acute posttraumatic bacterial endophthalmitis was 6.6% (4 eyes), the results of three cultures were negative. All endophthalmitis cases occurred in the BSS injection group; however, there was no statistically significant difference between case and control groups (p = 0.11). The incidence rate for those with retained intraocular foreign bodies was 13.3% and for those without foreign bodies was 4.4%. No retinal toxicity was detected.
CONCLUSION: Intraocular injection of gentamicin and clindamycin in addition to the other methods of prophylaxis may be an effective modality in the prevention of posttraumatic endophthalmitis. Early results suggest that these antibiotics may have a role as adjunct therapy to primary repair of injured globes without significant side effects at the dosage used.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 14750569     DOI: 10.1023/b:inte.0000006768.66170.c1

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  16 in total

1.  Antibiotic administration in the treatment of bacterial endophthalmitis. II. Intravitreal injections.

Authors:  G A Peyman
Journal:  Surv Ophthalmol       Date:  1977 Jan-Feb       Impact factor: 6.048

2.  Intraocular penetration of gentamicin after subconjunctibal and retrobulbar injection .

Authors:  M Barza; A Kane; J Baum
Journal:  Am J Ophthalmol       Date:  1978-04       Impact factor: 5.258

3.  Prognostic factors in ocular injuries caused by intraocular or retrobulbar foreign bodies.

Authors:  J B Jonas; H L Knorr; W M Budde
Journal:  Ophthalmology       Date:  2000-05       Impact factor: 12.079

4.  Endophthalmitis following penetrating eye injuries.

Authors:  A M Duch-Samper; J L Menezo; M Hurtado-Sarrió
Journal:  Acta Ophthalmol Scand       Date:  1997-02

5.  Intravenous cefazolin in penetrating eye injuries. I. Effects of trauma and multiple doses on intraocular delivery.

Authors:  D V Alfaro; P E Liggett
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-04       Impact factor: 3.117

6.  Endophthalmitis: incidence, therapy and visual outcome in the period 1983-1992 in the Rotterdam Eye Hospital.

Authors:  M V Joosse; C J van Tilburg; D A Mertens; E Peperkamp; J C van Meurs; P J Ringens; G V Jager; W H Beekhuis
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

7.  Rural endophthalmitis.

Authors:  H C Boldt; J S Pulido; C F Blodi; J C Folk; T A Weingeist
Journal:  Ophthalmology       Date:  1989-12       Impact factor: 12.079

8.  Useful visual outcomes after treatment of Bacillus cereus endophthalmitis.

Authors:  R E Foster; J A Martinez; T G Murray; P E Rubsamen; H W Flynn; R K Forster
Journal:  Ophthalmology       Date:  1996-03       Impact factor: 12.079

9.  Intravenous cefazolin in penetrating eye injuries. Treatment of experimental posttraumatic endophthalmitis.

Authors:  D V Alfaro; T Runyan; E Kirkman; V T Tran; P E Liggett
Journal:  Retina       Date:  1993       Impact factor: 4.256

10.  Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1995-12
View more
  6 in total

1.  Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial.

Authors:  Nader Baharivand; Ali Mahdavifard; Rohollah Fadaei Fouladi
Journal:  Int Ophthalmol       Date:  2012-09-28       Impact factor: 2.031

2.  Comparative evaluation of aqueous and plasma concentration of topical moxifloxacin alone and with flurbiprofen in patients of cataract surgery.

Authors:  Sujash Halder; Kanchan Kumar Mondal; Supreeti Biswas; Tapan Kumar Mandal; Bakul Kumar Dutta; Mithilesh Haldar
Journal:  Indian J Pharmacol       Date:  2013 May-Jun       Impact factor: 1.200

3.  Survey of Intraocular Antibiotics Prophylaxis Practice after Open Globe Injury in China.

Authors:  Bingsheng Lou; Lixia Lin; Junlian Tan; Yao Yang; Zhaohui Yuan; Xiaofeng Lin
Journal:  PLoS One       Date:  2016-06-08       Impact factor: 3.240

Review 4.  Role of intravitreal/intracameral antibiotics to prevent traumatic endophthalmitis - Meta-analysis.

Authors:  Thanigasalam Thevi; Adinegara Lutfi Abas
Journal:  Indian J Ophthalmol       Date:  2017-10       Impact factor: 1.848

5.  Rate of Post-traumatic Endophthalmitis with or without Injection of Balanced Salt Solution.

Authors:  Nasrin Rafati; Mohsen Azarmina; Farid Zaeri; Shahin Yazdani; Roham Soheilian; Masoud Soheilian
Journal:  J Ophthalmic Vis Res       Date:  2013-07

6.  Epidemiological characteristics and prognostic factors of post-traumatic endophthalmitis.

Authors:  Bahram Bohrani Sefidan; Seyed Ali Tabatabaei; Mohammad Soleimani; Aliasghar Ahmadraji; Mansoor Shahriari; Mostafa Daraby; Amin Dehghani Sanij; Ali Mehrakizadeh; Bahareh Ramezani; Kasra Cheraqpour
Journal:  J Int Med Res       Date:  2022-02       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.